X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE PFIZER SUVEN LIFE/
PFIZER
 
P/E (TTM) x 19.0 36.4 52.2% View Chart
P/BV x 4.2 5.4 77.5% View Chart
Dividend Yield % 0.5 0.6 86.4%  

Financials

 SUVEN LIFE   PFIZER
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
PFIZER
Mar-18
SUVEN LIFE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2512,365 10.6%   
Low Rs1551,625 9.5%   
Sales per share (Unadj.) Rs49.1430.3 11.4%  
Earnings per share (Unadj.) Rs9.778.7 12.3%  
Cash flow per share (Unadj.) Rs11.493.2 12.2%  
Dividends per share (Unadj.) Rs1.5020.00 7.5%  
Dividend yield (eoy) %0.71.0 73.7%  
Book value per share (Unadj.) Rs60.3586.5 10.3%  
Shares outstanding (eoy) m127.2845.75 278.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.6 89.1%   
Avg P/E ratio x20.925.3 82.4%  
P/CF ratio (eoy) x17.821.4 83.2%  
Price / Book Value ratio x3.43.4 98.9%  
Dividend payout %15.425.4 60.7%   
Avg Mkt Cap Rs m25,82591,271 28.3%   
No. of employees `0001.12.6 40.8%   
Total wages/salary Rs m6133,143 19.5%   
Avg. sales/employee Rs Th5,832.67,484.8 77.9%   
Avg. wages/employee Rs Th571.51,195.0 47.8%   
Avg. net profit/employee Rs Th1,153.81,369.1 84.3%   
INCOME DATA
Net Sales Rs m6,25319,685 31.8%  
Other income Rs m2331,143 20.4%   
Total revenues Rs m6,48520,828 31.1%   
Gross profit Rs m1,9825,003 39.6%  
Depreciation Rs m213663 32.2%   
Interest Rs m464 1,102.4%   
Profit before tax Rs m1,9555,479 35.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,878 38.2%   
Profit after tax Rs m1,2373,601 34.4%  
Gross profit margin %31.725.4 124.7%  
Effective tax rate %36.734.3 107.2%   
Net profit margin %19.818.3 108.1%  
BALANCE SHEET DATA
Current assets Rs m5,62224,167 23.3%   
Current liabilities Rs m1,1689,544 12.2%   
Net working cap to sales %71.274.3 95.9%  
Current ratio x4.82.5 190.2%  
Inventory Days Days8155 147.8%  
Debtors Days Days3629 125.2%  
Net fixed assets Rs m3,3259,514 34.9%   
Share capital Rs m127458 27.8%   
"Free" reserves Rs m7,54726,375 28.6%   
Net worth Rs m7,67426,832 28.6%   
Long term debt Rs m1425 55.6%   
Total assets Rs m9,13536,900 24.8%  
Interest coverage x43.21,305.5 3.3%   
Debt to equity ratio x00 194.4%  
Sales to assets ratio x0.70.5 128.3%   
Return on assets %14.09.8 143.8%  
Return on equity %16.113.4 120.1%  
Return on capital %26.020.4 127.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06622 22,616.5%   
Fx outflow Rs m2,0011,489 134.4%   
Net fx Rs m3,065-1,466 -209.0%   
CASH FLOW
From Operations Rs m6993,318 21.1%  
From Investments Rs m-6-2,383 0.3%  
From Financial Activity Rs m-577-1,104 52.3%  
Net Cashflow Rs m116-169 -69.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.7 154.0%  
Shareholders   37,287 85,207 43.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 21, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - DIVIS LABORATORIES COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS